- Home
- LEXX vs XAIR Comparison
LEXX vs XAIR Comparison
Compare LEXX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- XAIR
- Stock Information
- Founded
- LEXX 2004
- XAIR 2011
- Country
- LEXX Canada
- XAIR United States
- Employees
- LEXX N/A
- XAIR N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- LEXX Health Care
- XAIR Health Care
- Exchange
- LEXX Nasdaq
- XAIR Nasdaq
- Market Cap
- LEXX 25.8M
- XAIR 27.7M
- IPO Year
- LEXX N/A
- XAIR N/A
- Fundamental
- Price
- LEXX $1.45
- XAIR $0.26
- Analyst Decision
- LEXX Strong Buy
- XAIR Strong Buy
- Analyst Count
- LEXX 1
- XAIR 4
- Target Price
- LEXX $7.00
- XAIR $3.67
- AVG Volume (30 Days)
- LEXX 128.9K
- XAIR 1.7M
- Earning Date
- LEXX 04-08-2025
- XAIR 02-10-2025
- Dividend Yield
- LEXX N/A
- XAIR N/A
- EPS Growth
- LEXX N/A
- XAIR N/A
- EPS
- LEXX N/A
- XAIR N/A
- Revenue
- LEXX $496,923.00
- XAIR $3,023,000.00
- Revenue This Year
- LEXX $30.72
- XAIR $244.61
- Revenue Next Year
- LEXX $31.85
- XAIR $258.76
- P/E Ratio
- LEXX N/A
- XAIR N/A
- Revenue Growth
- LEXX 77.63
- XAIR 338.75
- 52 Week Low
- LEXX $1.15
- XAIR $0.25
- 52 Week High
- LEXX $6.85
- XAIR $1.86
- Technical
- Relative Strength Index (RSI)
- LEXX 43.81
- XAIR 32.89
- Support Level
- LEXX $1.15
- XAIR $0.25
- Resistance Level
- LEXX $1.44
- XAIR $0.31
- Average True Range (ATR)
- LEXX 0.14
- XAIR 0.04
- MACD
- LEXX 0.01
- XAIR -0.01
- Stochastic Oscillator
- LEXX 58.82
- XAIR 12.89
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.